Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01792284 · ClinicalTrials.gov registry record · Phase 3
A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 212
- Enrollment target
NCT01792284 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 212 participants.
The verdict
NCT01792284, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 212 participants
- Enrollment target
Study Summary
The primary purpose of participation in this study is to compare the safety and efficacy of different dosing schedules of LY2605541 and how different dosing schedules of LY2605541 affect Hemoglobin A1c (HbA1c). Participants will be treated for up to 36 weeks with LY2605541 (one 12-week Lead-in period and two 12-week Randomization periods) and will participate in a total of 42 weeks of total study enrollment, including a 2-week Screening period and a 4-week Follow-up period.
Interventions
- DRUG Insulin Lispro
- DRUG LY2605541
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2013-02 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01792284
The ClinicalTrials.gov registry entry for NCT01792284 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin Lispro is the first listed.
NCT01792284 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01792284 about?
NCT01792284 is a clinical study titled "A Study of LY2605541 in Participants With Type 1 Diabetes Mellitus". The primary purpose of participation in this study is to compare the safety and efficacy of different dosing schedules of LY2605541 and how different dosing schedules of LY2605541 affect Hemoglobin A1c (HbA1c). Participants will be treated for up to 36 weeks with LY2605541 (one 12-week Lead-in perio...
What is the current status of trial NCT01792284?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 212 participants. The study started on 2013-02. Estimated completion is 2014-04.
What interventions are being tested in trial NCT01792284?
The interventions under investigation include: Insulin Lispro (DRUG), LY2605541 (DRUG).
Who is sponsoring clinical trial NCT01792284?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.